Alberto Martini: Oncologic surveillance after surgical treatment for clinically localized kidney cancer
Alberto Martini, Assistant Professor and Director of Research at the Division of Urology at University of Cincinnati, posted the following on X:
“Long overdue, but finally out:
Oncologic surveillance after surgical treatment for clinically localized kidney cancer: UroCCR 129.
In 2021, the European Association of Urology EAU Guidelines implemented a novel, expert opinion-based follow-up scheme, with a three-risk-category system.
For clear cell (cc) and non-cc renal cell carcinoma (non-ccRCC) after surgery with curative intent.
In our study, we aimed to validate the follow-up scheme and provide data-driven recurrence estimates according to risk groups, to confirm or implement the surveillance strategy
We identified 5,320 patients from a prospectively maintained database involving 28 French referral centers. The risk of recurrence, as either loco-regional or distant, was evaluated for each group (low- intermediate- or high-risk) according to ccRCC or non-ccRCC histology.
Based on the low recurrence risk of patients with intermediate risk non-clear cell histology, patients falling in this category could be followed up with a similar strategy to those falling in the low-risk category.
Similarly, patients with high-risk non-clear cell histology with negative imaging at 3 months, could be followed up similarly to individuals with clear cell disease falling in the intermediate risk group after the 3-month time point.
We proposed a revision of the oncologic surveillance intensity to the current EAU follow-up scheme. Our proposed revision of the follow-up strategy could potentially result in lower imaging per patient, hence reducing follow-up related costs and radiation exposure.
”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023